With the launch of JLINX in April 2016, Johnson & Johnson Innovation further expanded the reach and diversity of its company incubation model. Based at the Janssen R&D campus in Beerse, Belgium, this multifaceted initiative is designed to nurture young companies in Europe with the potential to deliver healthcare breakthroughs.
ProteoFormiX is one of the first JLINX residents on the Beerse campus.
Browse the full report in The Pharma Frontier: digital magazine.
Read the report by Gazet Van Antwerpen online.